Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation

Liver Transplantation

Volumn 18, Issue 9, 2012, Pages 1053-1059

  Fontana, Robert J ^a   Hughes, Eric A ^c   Appelman, Henry ^b   Hindes, Robert ^d   Dimitrova, Dessislava ^c   Bifano, Marc ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLATASVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PREDNISONE; RIBAVIRIN; STEROID; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CHOLESTASIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT RESPONSE;

ALKALINE PHOSPHATASE; ANTIVIRAL AGENTS; BILIRUBIN; BIOLOGICAL MARKERS; CHOLESTASIS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER FAILURE; LIVER TRANSPLANTATION; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; REOPERATION; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84865602983     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23482     Document Type: Article

References (42)

1. Verna EC, Brown RS Jr,. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10: 919-940. (Pubitemid 44895436)
2. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177. (Pubitemid 26021616)
3. Prieto M, Berenguer M, Rayõn JM, Cõrdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-256. (Pubitemid 29024010)
4. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820. (Pubitemid 26099603)
5. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayõn M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684. (Pubitemid 30180389)
6. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896. (Pubitemid 34267271)
7. Lai JC, Verna EC, Brown RS Jr, O'Leary JG, Trotter JF, Forman LM, et al.; for Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011; 54: 418-424.
8. Guillouche P, Féray C,. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011; 33: 163-174.
9. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100-1108 (Pubitemid 47305028)
10. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN,. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008; 14: 53-58. (Pubitemid 351167989)
11. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008; 8: 2426-2433.
12. Carriõn JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756. (Pubitemid 46695723)
13. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465. (Pubitemid 46185706)
14. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al.; for REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
15. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al.; for ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
16. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; for SPRINT-2 Investigators. N Engl J Med 2011; 364: 1195-1206.
17. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.; for HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
18. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X,. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
19. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V,. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; 55: 4569-4574.
20. Fridell RA, Wang C, Sun JH, O'Boyle DR II, Nower P, Valera L, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924-1935.
21. Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54: 1956-1965.
22. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-748.
23. Suzuki F, Chayama K, Kawakami Y, Toyota J, Karinon Y, Mochida S, et al. Daclatasvir (DCV: BMS-790052), an NS5A replication complex inhibitor, in combination with peginterferon alfa-2b and ribavirin in Japanese treatment naïve and non-responder patients with chronic HCV genotype 1 infection [abstract]. Hepatology 2011; 54 (suppl 1): LB22.
24. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224.
25. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran S, et al. Daclatasvir (DCV; BMS-790052), an NS5A replication complex inhibitor, combined with peginterferon-alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase COMMAND-1 study interim week 24 results [abstract]. Hepatology 2011; 54:(suppl 1): A227.
26. Bifano M, Sevinsky H, Persson A, Hwang C, Kandoussi H, Jian H, et al. Daclatasvir (DCV; BMS-790052) has no clinically significant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects [abstract]. Hepatology 2011; 54:(suppl 1): A1340.
27. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-34.
28. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84-92. (Pubitemid 38116877)
29. Narang TK, Ahrens W, Russo MW,. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010; 16: 1228-1235.
30. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971-976. (Pubitemid 26137034)
31. Berenguer M, Prieto M, Palau A, Rayõn JM, Carrasco D, Juan FS, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003; 9: 228-235. (Pubitemid 36322323)
32. Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM,. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 2005; 11: 434-440. (Pubitemid 40533212)
33. Alcaide ML, Abbo L, Pano JR, Gaynor JJ, Tryphonopoulos P, Weppler D, et al. Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab. Clin Transplant 2008; 22: 502-507.
34. Levitsky J, Kalil A, Meza JL, Hurst GE, Freifeld A,. Herpes zoster infection after liver transplantation: a case-control study. Liver Transpl 2005; 11: 320-325. (Pubitemid 40458405)
35. Naoum C, Perissios A, Varnavas V, Lagos D,. Treatment of herpes zoster with interferon alpha-2A. Int J Dermatol 1996; 35: 749-750. (Pubitemid 26356133)
36. Selzner N, Guindi M, Renner EL, Berenguer M,. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207-217.
37. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132-1139.
38. Weston SJ, Leistikow RL, Reddy KR, Torres M, Wertheimer AM, Lewinsohn DM, et al. Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation. Hepatology 2005; 41: 72-81. (Pubitemid 40068845)
39. Sharma P, Jafri M, Appelman H, McKenna B, Sullivan P, Fontana RJ, Lok ASF,. Immunological dysfunction on antiviral therapy for hepatitis C recurrence after liver transplantation is associated with poor graft survival [abstract]. Am J Transplant 2011; 11: A828.
40. Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003; 9: 1159-1165. (Pubitemid 37407984)
41. Sulkowski MJ, Gardiner D, Lawitz E, Hinestrosa F, Nelson D, Thuluvath P, et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/- ribavirin, in treatment naïve patients with chronic HCV genotype 1, 2, and 3 [abstract]. J Hepatol 2012; 56.
42. Suzuki F, Ikeda K, Toyota J, Karino Y, Ohmura T, Chayama K, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1 infected null responders or patients ineligible/intolerant to peginterferon/ribavirin [abstract]. J Hepatol 2012; 56.